FY2026 · ended Jun 30, 2026 · Revenue $127,637 · Filed Oct 13, 2026
Advanced Biomed Inc. (ADVB) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $127,637 and net income of $6.7 million.
Revenue
$127,637
Net income
$6.68M
+304.9% vs prior year
Operating cash flow
$-1.95M
+66.6% vs prior year
Free cash flow
$-5.86M
EPS
$5.33
+267.6% vs prior year
Dividend per share
None
Shares outstanding
1.65M
-92.4% vs prior year
Net cash
$-10,551
FY 2025
Operating margin
-4883.8%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- ADVB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Reno, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1941029
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
|---|---|---|
| Revenue | $127,637 | — |
| Operating income | -$6.2M | — |
| Net income | $6.7M | -$3.3M |
| Diluted EPS | $5.33 | -$3.18 |
| Operating cash flow | -$1.9M | -$5.8M |
| Free cash flow | — | -$5.9M |
| Total assets | $13.8M | $22.9M |
| Total liabilities | $1.5M | $19.4M |
| Stockholders' equity | $12.3M | $3.5M |
| Cash and investments | $385,535 | $31,139 |
| Total debt | — | $41,690 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Agreement ended
|
Jul 17, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 30, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Officer or director change
|
May 1, 2026 | Apr 28, 2026 |
All 98 Advanced Biomed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.